Orphagen Pharmaceuticals
Biotechnology, Sorrento Vly Rd, San Diego, , 92121, California, 11558, United States, 1-10 Employees
Phone Number: 85********
Who is ORPHAGEN PHARMACEUTICALS
Orphagen discovers and develops small molecules to drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or orphan members of ...
Read More
-
Headquarters: 11558 Sorrento Vly Rd, San Diego, California, 92121, United States
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
CEO:
Scott Thacher
Email
Phone
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from ORPHAGEN PHARMACEUTICALS
Orphagen Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Orphagen Pharmaceuticals
Answer: Orphagen Pharmaceuticals's headquarters are located at Sorrento Vly Rd, San Diego, , 92121, California, 11558, United States
Answer: Orphagen Pharmaceuticals's phone number is 85********
Answer: Orphagen Pharmaceuticals's official website is https://orphagen.com
Answer: Orphagen Pharmaceuticals's revenue is $5 Million to $10 Million
Answer: Orphagen Pharmaceuticals's SIC: 2834
Answer: Orphagen Pharmaceuticals has 1-10 employees
Answer: Orphagen Pharmaceuticals is in Biotechnology
Answer: Orphagen Pharmaceuticals contact info: Phone number: 85******** Website: https://orphagen.com
Answer: Orphagen discovers and develops small molecules to drug targets that have significant unrealized potential in areas of high clinical need. We focus on the unexplored or orphan members of the nuclear receptor family. Nuclear receptors have been a rich source of successful drugs. Orphagen has identified drug-like small molecules to several orphan nuclear receptors and has described efficacy in animal models of disease. An early success led to a partnership with Japan Tobacco (JT) Pharma to discover and develop oral drugs to treat psoriasis and other autoimmune diseases. This partnership was the first in the industry for the nuclear receptor ROR-gamma. JTE-451, a product of the JT Pharma partnership, entered Phase 2 trials this year (in 2019). Orphagen has two major internal programs. One is to develop antagonists to the orphan nuclear receptor steroidogenic factor-1 (SF-1) for adrenocortical cancer (ACC) and other endocrine conditions. The second focuses on inflammatory disease.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month